Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18800440 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18738696 | VACCINE MOLECULES | June 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18668571 | USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALS | May 2024 | March 2025 | Allow | 10 | 0 | 0 | No | No |
| 18665920 | Compositions and Methods for Antigen Targeting to CD180 | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18662554 | METHODS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A PROTEIN | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18648190 | STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF | April 2024 | December 2024 | Allow | 7 | 0 | 0 | No | No |
| 18616134 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18612698 | SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE | March 2024 | November 2024 | Allow | 8 | 1 | 0 | No | No |
| 18612771 | MULTIVALENT EPSTEIN-BARR VIRUS-LIKE PARTICLES AND USES THEREOF | March 2024 | January 2025 | Allow | 10 | 1 | 0 | No | No |
| 18434265 | HEPATITIS B ANTIBODIES | February 2024 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18403182 | MULTIVALENT INFLUENZA NANOPARTICLE VACCINES | January 2024 | April 2025 | Allow | 16 | 2 | 0 | No | No |
| 18391486 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18527937 | Immunogenic Compositions to Treat and Prevent Microbial Infections | December 2023 | May 2025 | Allow | 17 | 1 | 1 | No | No |
| 18388788 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | November 2023 | June 2024 | Allow | 7 | 0 | 0 | No | No |
| 18493004 | SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTION | October 2023 | July 2024 | Allow | 9 | 1 | 1 | No | No |
| 18492095 | INDUCE AND ENHANCE IMMUNE RESPONSES USING RECOMBINANT REPLICON SYSTEMS | October 2023 | December 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18486459 | MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18480851 | METHOD FOR ROBUST CONTROL OF GENE EXPRESSION | October 2023 | January 2025 | Allow | 15 | 1 | 0 | No | No |
| 18463235 | ROTAVIRUS VACCINES | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18237718 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | August 2023 | July 2024 | Allow | 10 | 1 | 0 | No | No |
| 18235464 | COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOF | August 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18346456 | GENETICALLY ENCODED POLYPEPTIDE FOR AFFINITY CAPTURE AND PURIFICATION OF BIOLOGICS | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18344909 | INFLUENZA VACCINES | June 2023 | October 2024 | Allow | 16 | 1 | 0 | No | No |
| 18333591 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | June 2023 | August 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18332022 | MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUS | June 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18296150 | UNIVERSAL MAMMALIAN INFLUENZA VACCINE | April 2023 | April 2025 | Allow | 24 | 4 | 0 | Yes | No |
| 18295994 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | April 2023 | June 2024 | Allow | 15 | 2 | 0 | No | No |
| 18185891 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES | March 2023 | March 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18179668 | MARBURGVIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | March 2023 | December 2024 | Allow | 21 | 2 | 0 | No | No |
| 18077277 | MARKER COMBINATIONS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOF | December 2022 | April 2025 | Allow | 28 | 3 | 0 | No | No |
| 18052541 | HENIPAVIRUS VACCINE | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17937719 | RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE | October 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 17951674 | VIRUS AND ANTIGEN CONJUGATION | September 2022 | September 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17930065 | LASSA VIRUS VACCINE | September 2022 | June 2024 | Allow | 22 | 1 | 0 | No | No |
| 17851187 | NON-COVALENT LOADING OF PLANT PICOVIRUS PARTICLES | June 2022 | November 2024 | Allow | 28 | 3 | 0 | No | No |
| 17750612 | VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY | May 2022 | August 2024 | Allow | 27 | 1 | 0 | No | No |
| 17719751 | METHOS FOR RAPID DETECTION AND IDENTIFICATION OF VIRAL NUCLEIC ACIDS | April 2022 | May 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17706381 | VIRAL VACCINES AND METHODS OF FORMING THE SAME | March 2022 | June 2025 | Allow | 38 | 1 | 0 | No | No |
| 17623525 | Recombinant Herpes Zoster Vaccine Composition and Application Thereof | December 2021 | May 2025 | Allow | 40 | 1 | 0 | No | No |
| 17543206 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | December 2021 | March 2025 | Allow | 39 | 1 | 0 | No | No |
| 17596162 | Designed Inhibitors of Tight Junction Formation | December 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17613331 | NOROVIRUS-BINDING PEPTIDE | November 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17612208 | VACCINE SPRAY EQUIPMENT | November 2021 | June 2025 | Allow | 43 | 1 | 0 | No | No |
| 17606811 | A SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTION | October 2021 | July 2024 | Allow | 33 | 1 | 0 | No | No |
| 17438178 | DENGUE VIRUS VACCINE | October 2021 | February 2025 | Allow | 41 | 1 | 0 | No | No |
| 17480073 | COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS, AND METHODS OF USING THE SAME | September 2021 | March 2025 | Allow | 41 | 1 | 0 | No | No |
| 17435145 | PORCINE EPIDEMIC DIARRHEA (PED) VIRUS VACCINE COMPOSITION AND PREPARATION METHOD THEREOF | August 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17424494 | Means and Methods for Improving Plant Growth and Yield | July 2021 | October 2024 | Allow | 39 | 1 | 1 | No | No |
| 17413331 | RECOMBINANT MUMPS VIRUS VACCINE EXPRESSING GENOTYPE G FUSION AND HEMAGGLUTININ-NEURAMINIDASE PROTEINS | June 2021 | May 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17413026 | HEPATITIS B VIRUS VACCINE AND USES THEREOF | June 2021 | April 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17413130 | INTEGRATED PROVIRAL SEQUENCING ASSAY | June 2021 | August 2024 | Allow | 39 | 1 | 0 | No | No |
| 17327784 | SARS-COV-2 Antigen Polypeptide, Recombinant Adeno-Associated Virus Expressing the Polypeptide, and Vaccine Containing the Virus | May 2021 | November 2024 | Allow | 42 | 1 | 1 | No | No |
| 17318719 | Stabilizing Mutants of Prefusion Sars-Cov-2 (Covid-19) Spike Protein And Improved Yeast Surface Display Engineering Platform For The Same | May 2021 | February 2025 | Allow | 45 | 4 | 1 | Yes | No |
| 17240858 | ENGINEERED CRISPR-CAS SYSTEMS AND METHODS FOR SENSITIVE AND SPECIFIC DIAGNOSTICS | April 2021 | February 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17288133 | PEPTIDES FOR INDUCING HETEROSUBTYPIC INFLUENZA T CELL RESPONSES | April 2021 | November 2024 | Allow | 43 | 1 | 0 | No | No |
| 17236516 | VIRUS DETECTION SYSTEM, VIRUS DETECTION METHOD, AND VIRUS DETECTION PROGRAM | April 2021 | December 2024 | Allow | 43 | 1 | 1 | No | No |
| 17276649 | MUCOADHESIVE LIPIDIC DELIVERY SYSTEM | March 2021 | December 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17274891 | ADENOSOMES | March 2021 | June 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17194308 | VIRAL PANDEMIC VACCINE | March 2021 | June 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17268314 | GENETICALLY ENCODED POLYPEPTIDE FOR AFFINITY CAPTURE AND PURIFICATION OF BIOLOGICS | February 2021 | October 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17264649 | T CELL RECEPTOR FOR IDENTIFYING AFP ANTIGEN | January 2021 | July 2024 | Allow | 41 | 1 | 0 | No | No |
| 17263606 | METHOD FOR ENHANCING GENE EXPRESSION USING AAV VECTOR | January 2021 | August 2024 | Allow | 43 | 1 | 0 | No | No |
| 15733861 | COMBINED PROPHYLACTIC AND THERAPEUTIC VACCINES | November 2020 | August 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17055096 | BINDING MOIETY FOR CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES | November 2020 | April 2025 | Allow | 53 | 1 | 0 | No | No |
| 16604711 | NOVEL DELIVERY OF LARGE PAYLOADS | October 2019 | February 2025 | Allow | 60 | 2 | 1 | No | No |
| 16287559 | HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES | February 2019 | February 2020 | Allow | 11 | 2 | 0 | Yes | No |
| 16025624 | CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS | July 2018 | June 2019 | Allow | 11 | 1 | 0 | No | No |
| 15579150 | VIRAL CHIMERIC PARTICLE OF POTATO VIRUS X AND USE THEREOF FOR IN VITRO DIAGNOSIS OF SJ�GREN SYNDROME | December 2017 | February 2020 | Allow | 26 | 1 | 1 | No | No |
| 15508670 | MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES | March 2017 | December 2018 | Allow | 21 | 1 | 1 | No | No |
| 15507676 | ANTI-HEPATITIS C ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF | February 2017 | May 2019 | Allow | 26 | 2 | 0 | Yes | No |
| 15501339 | LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUG | February 2017 | June 2019 | Allow | 28 | 2 | 1 | No | No |
| 15079013 | HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES | March 2016 | September 2018 | Allow | 30 | 1 | 1 | No | No |
| 15042436 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE | February 2016 | July 2017 | Allow | 17 | 0 | 1 | Yes | No |
| 15040277 | INFLUENZA VIRUS MUTANTS AND USES THEREFOR | February 2016 | November 2017 | Allow | 21 | 1 | 0 | No | No |
| 15040705 | INFLUENZA VIRUS MUTANTS AND USES THEREFOR | February 2016 | November 2017 | Allow | 21 | 1 | 0 | No | No |
| 14900834 | Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector | December 2015 | March 2019 | Allow | 39 | 2 | 1 | No | No |
| 14945384 | HEPATITIS B VIRUS PRE-S1 DERIVED SYNTHETIC POLYPEPTIDES AND USES THEREOF | November 2015 | March 2019 | Allow | 39 | 3 | 0 | Yes | No |
| 14926989 | METHOD OF DIAGNOSING AND TREATING EPSTEIN BARR VIRUS-BASED MYALGIC ENCEPHALOMYELITIS CHRONIC FATIGUE SYNDROME PATIENTS | October 2015 | September 2018 | Allow | 35 | 2 | 1 | No | No |
| 14725508 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE | May 2015 | November 2016 | Allow | 18 | 0 | 0 | No | No |
| 14454341 | NOVEL COMPOSITIONS AND USES THEREFOR | August 2014 | January 2018 | Allow | 41 | 3 | 1 | No | No |
| 14335511 | IN SITU DETECTION OF EARLY STAGES AND LATE STAGES HPV INFECTION | July 2014 | September 2016 | Allow | 26 | 2 | 1 | No | No |
| 14296095 | INFLUENZA VIRUS-LIKE PARTICLE (VLP) COMPOSITIONS | June 2014 | March 2016 | Allow | 21 | 2 | 0 | No | No |
| 14360524 | HPV Chimaeric Particle | May 2014 | May 2017 | Allow | 36 | 3 | 1 | Yes | No |
| 14131616 | Vaccine Composition With Aluminium Hydroxide Nanoparticles | April 2014 | May 2017 | Allow | 41 | 3 | 1 | No | No |
| 14342129 | NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 3a | April 2014 | June 2016 | Allow | 27 | 1 | 1 | No | No |
| 14175892 | METHODS OF MODULATING HVEM, BTLA AND CD160 CIS COMPLEX RESPONSE OR SIGNALING ACTIVITY WITH SOLUBLE LIGHT POLYPEPTIDE SEQUENCES | February 2014 | October 2018 | Allow | 57 | 5 | 0 | No | No |
| 14000815 | MULTIMERIC MULTIEPITOPE POLYPEPTIDES IN IMPROVED SEASONAL AND PANDEMIC INFLUENZA VACCINES | December 2013 | January 2016 | Allow | 29 | 2 | 1 | No | No |
| 14138991 | HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES | December 2013 | February 2016 | Allow | 26 | 1 | 1 | No | No |
| 14127052 | EPITOPE AND ITS USE OF HEPATITIS B VIRUS SURFACE ANTIGEN | December 2013 | May 2016 | Allow | 29 | 2 | 1 | No | No |
| 14073488 | HCV GENOTYPE 6 REPLICONS | November 2013 | January 2016 | Allow | 36 | 2 | 1 | Yes | No |
| 13641560 | AGENT FOR USE IN THE TOPICAL OR LOCAL TREATMENT OF CERVICAL DYSPLASIAS | October 2012 | March 2014 | Allow | 17 | 2 | 1 | Yes | No |
| 13553137 | PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDES | July 2012 | December 2015 | Allow | 41 | 2 | 1 | Yes | No |
| 13540421 | RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE TRANSPORTER (NIS) | July 2012 | October 2013 | Allow | 15 | 1 | 0 | No | No |
| 13532425 | VACCINES CONTAINING CANINE PARVOVIRUS GENETIC VARIANTS | June 2012 | August 2013 | Allow | 13 | 1 | 1 | No | No |
| 13528407 | HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR | June 2012 | May 2014 | Allow | 23 | 1 | 1 | No | No |
| 13511116 | HEPATITUS B VIRUS SPECIFIC ANTIBODY AND USESE THEREOF | May 2012 | January 2016 | Allow | 44 | 3 | 1 | No | No |
| 13499488 | ADJUVANTED VACCINE FORMULATIONS | May 2012 | May 2017 | Allow | 60 | 5 | 1 | Yes | No |
| 13462314 | VACCINE FOR MODULATING BETWEEN T1 AND T2 IMMUNE RESPONSES | May 2012 | May 2013 | Allow | 13 | 1 | 0 | No | No |
| 13364952 | MINIMAL MOTIFS OF LINEAR B-CELL EPITOPES IN L1 PROTEIN FROM HUMAN PAPILLOMAVIRUS TYPE 58 AND THEIR APPLICATIONS | February 2012 | February 2014 | Allow | 24 | 1 | 1 | No | No |
| 13254039 | METHODS FOR PROLIFERATION OF ANTIGEN-SPECIFIC T CELLS | January 2012 | April 2015 | Allow | 44 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOESEN, AGNIESZKA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BOESEN, AGNIESZKA works in Art Unit 1671 and has examined 179 patent applications in our dataset. With an allowance rate of 92.2%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner BOESEN, AGNIESZKA's allowance rate of 92.2% places them in the 77% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by BOESEN, AGNIESZKA receive 2.39 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BOESEN, AGNIESZKA is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +5.8% benefit to allowance rate for applications examined by BOESEN, AGNIESZKA. This interview benefit is in the 32% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 31.7% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 46.3% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 69.0% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 16.2% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.